EAPH-04. SAFETY AND TOLERABILITY OF CONCOMITANT MULTI-AGENT INTRA-VENTRICULAR CHEMOTHERAPY FOR THE TREATMENT OF RECURRENT CENTRAL NERVOUS SYSTEM (CNS) TUMORS

類似資料

• MBCL-33. HEPATOTOXICITY DURING INDUCTION CHEMOTHERAPY, WITH OR WITHOUT HIGH-DOSE METHOTREXATE (HD-MTX), ON THE HEAD START II TRIAL FOR PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
  著者:: Abu Arja, Mohammad H, 等
  出版事項: (2018)
• GERM-02. NOVEL TREATMENT APPROACH FOR PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) PURE EMBRYONAL CARCINOMA WITH INTENSIVE INDUCTION AND CONSOLIDATION MARROW-ABLATIVE CHEMOTHERAPY FOLLOWED BY AN ANTI-CD30 ANTIBODY-DRUG CONJUGATE, WITHOUT IRRADIATION
  著者:: Abu Arja, Mohammad H, 等
  出版事項: (2018)
• GC-04 PRELIMINARY RESULTS OF A FEASIBILITY PILOT STUDY OF “GEMPOX” (GEMCITABINE, OXALIPLATIN, AND PACLITAXEL) IN PEDIATRIC AND ADULT PATIENTS WITH REFRACTORY OR RECURRENT CENTRAL NERVOUS SYSTEM (CNS) GERM CELL TUMORS (GCT): THE INTERNATIONAL CNS GCT CONSORTIUM TRIAL, CNS GCT- 4
  著者:: Finlay, Jonathan, 等
  出版事項: (2015)
• GCT-40. PROGNOSTIC FACTORS FOR PATIENTS WITH RELAPSED CENTRAL NERVOUS SYSTEM (CNS) NON-GERMINOMATOUS GERM CELL TUMORS (NGGCTs)
  著者:: Abu-Arja, Mohammad H, 等
  出版事項: (2020)
• GERM-01. RESPONSE RATES TO DIFFERENT RE-INDUCTION CHEMOTHERAPY REGIMENS IN PATIENTS WITH RECURRENT CENTRAL NERVOUS SYSTEM MIXED MALIGNANT GERM CELL TUMORS
  著者:: Abu Arja, Mohammad H, 等
  出版事項: (2018)